Physician profile
Andrew B Repasy
NPI 1942383872
$2,488.96
in general payments reported to CMS, 2019-2025
24 companies · $23.93 in 2025
The $23.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $226 · 2021: $1,200 · 2023: $173 · 2024: $27.96 · 2025: $23.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Novo Nordisk INC | $172.72 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $171.94 | 2019-2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $128.08 | 2019 | |
| Amgen INC. | $104.45 | 2019-2020 | |
| Pfizer INC. | $69.98 | 2019 | |
| Exact Sciences Corporation | $52.72 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $49.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.17 | 2019-2025 | Capvaxive, Gardasil 9 |
| Ironwood Pharmaceuticals, INC | $40.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $40.01 | 2019-2020 | |
| Allergan, INC. | $38.31 | 2019-2020 | |
| Bausch Health US, LLC | $35.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.45 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $27.91 | 2023 | Rexulti |
| Lilly USA, LLC | $22.26 | 2023 | Jardiance |
| Horizon Therapeutics Plc | $21.81 | 2023 | Krystexxa |
| Genentech USA, INC. | $20.83 | 2019 | |
| Sanofi Pasteur INC. | $19.33 | 2019 | |
| Alfasigma USA, INC. | $18.26 | 2020 | |
| Shire North American Group INC | $15.79 | 2019 | |
| Braintree Laboratories, INC. | $15.75 | 2019 | |
| Metuchen Pharmaceuticals | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Repasy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.